Shares of Swiss pharmaceutical giant Roche advanced to a multi-year peak on Friday, closing 1.02% higher at 375.60 Swiss francs after briefly surpassing an intraday record set in February. The gain marked the highest level for Roche participation certificates since April 2022, leaving the all-time high of 404.20 francs just 7.6% away.
The rally follows a sustained upward trend, with Roche shares up 13% since July 22, outpacing the 1% gain in the Swiss Market Index (SMI) over the same period. Analysts attributed the outperformance to stronger-than-expected half-year results released at the end of July. Group revenue slightly exceeded market consensus while core operating profit (core EBIT) surpassed expectations by 4%.
Supporting sentiment, analysts highlighted Roche’s robust product pipeline, including several novel molecules. Stefan Schneider of Bank Vontobel noted in late July that the company’s pipeline is ‘as full as never before with promising candidates.’ Urban Fritsche of Zürcher Kantonalbank (ZKB) similarly emphasized that operational foundations are in place, though future revenue expectations hinge on upcoming news flow.
Key catalysts on the horizon include Roche’s London Pharma Day at the end of September, followed by U.S. regulatory decisions in November and December for the breast cancer drug giredestrant in two indications. Analysts project blockbuster potential for giredestrant, with peak annual sales estimated near 10 billion francs. However, Roche faces competition from AstraZeneca’s rival drug camizestrant.
Analyst actions have reflected the improved outlook. Morgan Stanley upgraded Roche from Equal Weight to Overweight in early August, raising its price target from 295 to 410 francs—another all-time high. Among 16 analysts tracked by AWP, eight recommend buying Roche shares, seven advise holding, and one suggests selling. The average price target stands at 368.84 francs, implying a 1.8% decline over the next 12 months, though further upward revisions remain possible.
Investors are expected to closely monitor developments, particularly around upcoming milestones. While momentum from recent sessions may carry into Monday trading, profit-taking and potential disappointments in the medium term cannot be ruled out.
